Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

3 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Testicular Cancer NCT02276430

- 28/09/2021 - 1 Formulaire, 3 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Additional inclusion criteria for participating in the cardiometabolic risk inventory study, Exclusion Criteria
TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects; ODM derived from: https://clinicaltrials.gov/show/NCT02276430

Cancer Report Form Repeating form GSK study Chronic Coronary Heart Disease NCT00799903

- 01/01/2018 - 1 Formulaire, 5 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Diagnosis of cancer, New cancer details, Recurrence of cancer details, Metastatic cancer details, Hospitalisation related to diagnosis
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Cancer Report Form - Repeating form (Scheduled visits)

Cancer GI Neoplasm Polyp Report Form GSK study Chronic Coronary Heart Disease NCT00799903

- 01/01/2018 - 1 Formulaire, 6 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Involvement of gastrointestinal system, Type of cancer, GI neoplasm or GI polyp diagnosis, New cancer or Recurrence or progression of cancer details, Benign GI polyps / neoplasms, Required source documents sent, CEC Status
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Cancer / GI Neoplasm / Polyp Report Form (CNP) - Repeating form (Scheduled visits)

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial